Timeline

Voting rights breakdown

Gemeldete wirtschaftlich Berechtigte · 21

Eine einzelne, gemeinsam eingereichte Meldung: Der Stimmrechtsanteil gilt für die gesamte Gruppe, nicht für jede Person.

• Aravis Venture I LP8.9%
• Astellas Venture Capital, LLC8.9%
• Auriga Ventures III8.9%
• Baltisches Haus Limited8.9%
• BioMedInvest II LP8.9%
• Dansk Innovationsinvestering P/S c/o LD Invest A/S8.9%
• Entrepreneurs Fund General Partners Limited8.9%
• Evolva Holding SA8.9%
• Mona Lisa Capital SA8.9%
• Novartis Bioventures Ltd8.9%
• Renaisance PME fondation suisse d investissement / Mona Lisa8.9%
• Sunstone Life Science Ventures Fund I K/S8.9%
• Symbion Capital I A/S8.9%
• Wellington Partners Ventures III Life Science Fund L.P8.9%
• Wellington Partners Ventures III Life Science Network Fund L8.9%
• Neil Goldsmith8.9%
• Alexandra SantAna Sørensen8.9%
• Pascal Longchamp8.9%
• Jakob Dynnes Hansen8.9%
• Jutta Heim8.9%
• PM Murali8.9%

Notice details

Beneficial owner

Aravis Venture I LP

The members of the group (the Sale Group) have agreed to execute a coordinated sale by way of block trades and sales on the market of the SIX Swiss Exchange Ltd. with regard to 10% of their aggregate holdings (i.e., with regard to 12,380,977 shares) up to and including May 23, 2011. Shares not sold on or before May 23, 2011 will be distributed to the group members and become freely tradeable on May 24, 2011. Additional information can be downloaded from the Evolva website: http://www.evolva.com/press-investors/investors/disclosure-shareholdings